Kodiak Sciences (KOD) CFO John A. Borgeson Sells $2.7M of Stock

Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson sold 30,000 shares of the company on October 21, 2026. The transaction was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission.

KOD Kodiak Sciences Inc.

$87.63 ▲ +236.78% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Inside John A. Borgeson's Kodiak Sciences Trade

The Chief Financial Officer executed the sale at an average price of $90.01 per share, netting a total value of roughly $2.7 million. This pre-arranged sale was carried out under a Rule 10b5-1 trading plan. Following the transaction, Borgeson retains 211,930 shares in the clinical-stage biopharmaceutical company, marking a 12.4% reduction in his personal holdings. This follows earlier sales by the CFO earlier in the year, including a 30,000-share sale on April 2, 2026, and another 30,000-share sale on June 4, 2026.

Other Institutional Activity in Kodiak Sciences

Large financial institutions adjusted their positions in Kodiak Sciences during the middle of the year. Baker Bros. Advisors, LP kept its holdings steady at 19,919,186 shares valued at about $1.75 billion. Braidwell LP reduced its stake by 31,280 shares, ending with 1,787,318 shares worth roughly $156.6 million. Jupiter Topco LLC grew its position significantly by adding 763,003 shares for a 100% increase, finishing with 1,526,006 shares worth about $133.7 million. RTW Investments LP maintained its position at 1,487,934 shares valued at $130.4 million. Boxer Capital Management, LLC grew its holdings by 116,635 shares, an 8.6% increase to 1,477,600 shares worth about $129.5 million.

Kodiak Sciences Inc. Stock Down 0.1%

Shares of Kodiak Sciences recently traded around $87.63. The stock sits well above its 50-day moving average of $57.28 and its 200-day moving average of $40.10. The shares trade below their 52-week high of $104.00 and well above their 52-week low of $15.83. The company carries a market capitalization of about $5.39 billion.

Recent Earnings

The company is not currently profitable, reporting a negative trailing twelve month earnings per share of $4.10 and a negative return on equity of 368.4%. Investors look ahead to the next corporate earnings update scheduled for November 12, 2026.

Insider Buying and Selling at Kodiak Sciences Inc.

Aside from the CFO's recent sales, insider activity in recent months included large purchases by major shareholder Baker Bros Advisors L.P. The firm bought 807,840 shares on September 28, 2026, worth about $62.1 million, followed by another purchase of 715,592 shares on September 29, 2026, worth about $63.4 million.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the autumn months. HC Wainwright & Co. reiterated a buy rating with a $58.00 target on September 17, 2026, before raising its target to $96.00 on September 28 and $126.00 on October 12. LifeSci Capital maintained an outperform rating and lifted its target from $85.00 to $145.00 on September 28. UBS maintained a buy rating and raised its target from $80.00 to $120.00 on September 28. The stock holds a consensus strong buy rating with an average price target of $121.67 across six analyst opinions.

About Kodiak Sciences Inc.

Based in Palo Alto, California, Kodiak Sciences is a clinical-stage biopharmaceutical firm focused on developing therapeutics to treat retinal diseases. The company employs 141 people and works on proprietary antibody biopolymer conjugates designed to improve patient outcomes in ophthalmology.

Bottom Line

The CFO's scheduled sale reduces his stake while large backers like Baker Bros continue to build major positions. Investors will watch the upcoming earnings report on November 12 to gauge progress on the company's clinical pipeline.